Wegovy Dosing for Weight Management
Wegovy (semaglutide) should be initiated at 0.25 mg subcutaneously once weekly for 4 weeks, then escalated every 4 weeks through 0.5 mg, 1.0 mg, and 1.7 mg, reaching the recommended maintenance dose of 2.4 mg weekly at week 17. 1
Standard Dose Escalation Schedule
The FDA-approved titration protocol is designed to minimize gastrointestinal adverse effects 2:
- Weeks 1-4: 0.25 mg once weekly
- Weeks 5-8: 0.5 mg once weekly
- Weeks 9-12: 1.0 mg once weekly
- Weeks 13-16: 1.7 mg once weekly
- Week 17 onward: 2.4 mg once weekly (recommended maintenance dose)
An alternative maintenance dose of 1.7 mg weekly may be considered based on individual response and tolerability 1.
Administration Details
- Inject subcutaneously in the abdomen, thigh, or upper arm
- Administer on the same day each week, at any time of day
- Can be given with or without meals
- Must be combined with reduced-calorie diet and increased physical activity 1
Managing Missed Doses
If one dose is missed:
- >48 hours until next scheduled dose: Administer immediately
- <48 hours until next scheduled dose: Skip the missed dose and resume regular schedule
If two or more consecutive doses are missed:
- Resume at the scheduled dose OR restart the entire titration schedule from 0.25 mg to reduce gastrointestinal symptoms 1
Dose Adjustment Considerations
If patients cannot tolerate a dose during escalation: Delay the next dose increase by 4 weeks 2. Clinical judgment should guide whether to continue at the current dose long-term, as some patients achieve adequate response at submaximal doses 2.
Real-world evidence shows significant deviation from this protocol: Only 13% of patients reach 2.4 mg by their fifth prescription, with 33-48% remaining on 1.0 mg from the fourth prescription onward 3. Despite slower titration and lower maintenance doses in clinical practice, substantial weight loss still occurs (mean -13.6% at 12 months) 4.
Critical Safety Monitoring
Before initiating treatment:
- Screen for personal or family history of medullary thyroid carcinoma or MEN 2 (absolute contraindications) 1
- In patients with type 2 diabetes, monitor blood glucose before starting and throughout treatment 1
During dose escalation:
- Monitor for severe gastrointestinal reactions (nausea, vomiting, diarrhea occur in 40-60% of patients) 2
- Watch for signs of acute pancreatitis, gallbladder disease, and acute kidney injury 1
- Check heart rate at regular intervals 1
- Monitor for depression or suicidal ideation 1
For patients on insulin or sulfonylureas: Reduce doses of these medications as clinically indicated to prevent hypoglycemia 2, 1
Common Pitfalls to Avoid
- Do not use with other GLP-1 receptor agonists or DPP-4 inhibitors 2
- Do not rush titration - the 4-week intervals between dose increases are essential for tolerability
- For planned surgeries: Instruct patients to inform healthcare providers due to delayed gastric emptying and aspiration risk during anesthesia 1
- For women of childbearing potential: Discontinue at least 2 months before planned pregnancy due to long half-life 1
Expected Outcomes
At the 2.4 mg maintenance dose, patients typically achieve:
- Mean weight loss of 14-15% at 68 weeks 2, 5
- 86% achieve ≥5% weight loss
- 69% achieve ≥10% weight loss
- 50% achieve ≥15% weight loss 2
The gradual titration schedule is non-negotiable for minimizing the predominantly gastrointestinal adverse effects that lead to treatment discontinuation in approximately 4-5% of patients 2, 5.